Saturn V Capital Management LP
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 15, 2025), Saturn V Capital Management LP reported 21 stock positions worth $198.2 million. Its top holding was Ascendis Pharma A/S (ASND) at 15.7% of the portfolio, followed by Disc Medicine (IRON, 13.0%) and CG Oncology (CGON, 7.1%). Compared with Q4 2024, it opened 1 new position, sold out of 4, added to 11 and reduced 9. The biggest buy was Ascendis Pharma A/S (ASND, shares +0%) and the biggest sale an exit from Cytokinetics (CYTK).
- Most Recent 13F
- Q2 2026
- Location
- AUSTIN, TX
- CIK
- 0001964437
- Portfolio Value
- $198.2M (Q1 2025)
- SEC Filing
- 0001964437-25-000005 ↗ filed May 15, 2025
Holdings Value
Holdings 21 stocks · $198.2M
| ASND Ascendis Pharma A/S | 15.67% | 199,264 | $31.1M | Add +0.1% |
| IRON Disc Medicine Inc. | 12.98% | 518,177 | $25.7M | Add +1.7% |
| CGON CG Oncology Inc. | 7.14% | 577,696 | $14.1M | Reduce -2.6% |
| XENE Xenon Pharmaceuticals Inc. | 7.00% | 413,711 | $13.9M | Add +28.3% |
| MRUS Merus NV | 6.87% | 323,211 | $13.6M | Add +37.8% |
| MLTX Moonlake Immunotherapeutics | 6.78% | 343,849 | $13.4M | Reduce -0.7% |
| SNDX Syndax Pharmaceuticals Inc. | 6.46% | 1,041,280 | $12.8M | Add +5.3% |
| CELC Celcuity Inc. | 5.58% | 1,093,677 | $11.1M | Add +2.8% |
| COGT Cogent Biosciences Inc. | 4.47% | 1,480,020 | $8.9M | Reduce -1.2% |
| PCVX Vaxcyte Inc. | 4.43% | 232,295 | $8.8M | Add +13.7% |
| AMLX Amylyx Pharmaceuticals Inc. | 4.33% | 2,426,436 | $8.6M | Add +172.9% |
| ARGX Argenx SE - ADR | 4.14% | 13,862 | $8.2M | Reduce -29.8% |
| CNTA Centessa Pharmaceuticals Ltd. | 3.26% | 448,692 | $6.5M | New |
| OCUL Ocular Therapeutix Inc. | 2.21% | 598,191 | $4.4M | Add +212.4% |
| CTNM Contineum Therapeutics Inc. Class A | 1.98% | 560,979 | $3.9M | Reduce -2.1% |
| ABVX Abivax SA-ADR | 1.74% | 552,926 | $3.5M | Reduce -15.3% |
| KALV Kalvista Pharmaceuticals Inc. | 1.49% | 255,060 | $2.9M | Reduce -54.2% |
| NAMS Newamsterdam Pharma Co. NV | 1.20% | 116,353 | $2.4M | Add +16.4% |
| SLN Silence Therapeutics PLC-ADR | 1.04% | 732,463 | $2.1M | Add +85.4% |
| CRNX Crinetics Pharmaceuticals Inc. | 1.00% | 59,017 | $2.0M | Reduce -0.2% |
| INZY Inozyme Pharma Inc. | 0.23% | 499,254 | $454K | Reduce -63.7% |
Portfolio Sells Q4 2024 → Q1 2025
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −6.42 |
| CRGX Cargo Therapeutics Inc. | Sold out | 0.00% | −5.69 |
| IRWD Ironwood Pharmaceuticals Inc. | Sold out | 0.00% | −1.41 |
| CTNM Contineum Therapeutics Inc. Class A | Reduce -2.1% | 1.98% | −1.31 |
| INZY Inozyme Pharma Inc. | Reduce -63.7% | 0.23% | −1.26 |
| ARGX Argenx SE - ADR | Reduce -29.8% | 4.14% | −0.62 |
| MLTX Moonlake Immunotherapeutics | Reduce -0.7% | 6.78% | −0.56 |
| KALV Kalvista Pharmaceuticals Inc. | Reduce -54.2% | 1.49% | −0.36 |
| CRNX Crinetics Pharmaceuticals Inc. | Reduce -0.2% | 1.00% | −0.18 |
| MBX MBX Biosciences Inc. | Sold out | 0.00% | −0.13 |
| ABVX Abivax SA-ADR | Reduce -15.3% | 1.74% | −0.13 |
| COGT Cogent Biosciences Inc. | Reduce -1.2% | 4.47% | −0.10 |
| CGON CG Oncology Inc. | Reduce -2.6% | 7.14% | +0.48 |
Portfolio Buys Q4 2024 → Q1 2025
| ASND Ascendis Pharma A/S | Add +0.1% | 15.67% | +4.95 |
| CNTA Centessa Pharmaceuticals Ltd. | New | 3.26% | +3.26 |
| AMLX Amylyx Pharmaceuticals Inc. | Add +172.9% | 4.33% | +3.02 |
| MRUS Merus NV | Add +37.8% | 6.87% | +3.00 |
| XENE Xenon Pharmaceuticals Inc. | Add +28.3% | 7.00% | +2.05 |
| OCUL Ocular Therapeutix Inc. | Add +212.4% | 2.21% | +1.57 |
| SNDX Syndax Pharmaceuticals Inc. | Add +5.3% | 6.46% | +1.34 |
| IRON Disc Medicine Inc. | Add +1.7% | 12.98% | +0.33 |
| NAMS Newamsterdam Pharma Co. NV | Add +16.4% | 1.20% | +0.20 |
| CELC Celcuity Inc. | Add +2.8% | 5.58% | +0.13 |
| SLN Silence Therapeutics PLC-ADR | Add +85.4% | 1.04% | −0.02 |
| PCVX Vaxcyte Inc. | Add +13.7% | 4.43% | −2.12 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 23 | $697.5M | AMLX, ALMS, ABVX, PCVX, IMMX |
| Q1 2026 | 21 | $552.2M | ALMS, AMLX, ABVX, PCVX, PHVS |
| Q4 2025 | 20 | $544.9M | ABVX, AMLX, COGT, JAZZ, PCVX |
| Q3 2025 | 17 | $456.0M | ABVX, AMLX, JAZZ, DYN, COGT |
| Q2 2025 | 24 | $246.8M | JAZZ, IRON, AMLX, PCVX, COGT |
| Q1 2025 | 21 | $198.2M | ASND, IRON, CGON, XENE, MRUS |
| Q4 2024 | 24 | $255.4M | IRON, ASND, MLTX, CGON, PCVX |
| Q3 2024 | 25 | $279.8M | ASND, IRON, PCVX, CGON, COGT |
| Q2 2024 | 26 | $264.6M | ARGX, IRON, CRNX, PCVX, ASND |
| Q1 2024 | 21 | $249.4M | CRNX, ARGX, CYTK, KALV, MRUS |